Sands JM, Champiat S, Hummel HD, Paulson KG, et al. Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer. Cancer 2025;131:e35738.
PMID: 39876075